Literature DB >> 33579808

Landscape Analysis of Phase 2 and 3 Clinical Trials for Targeted Radionuclide Therapy.

Erik Mittra1, Lisa Bodei2.   

Abstract

Entities:  

Keywords:  radioisotope therapy; radioligand therapy; radiopharmaceutical therapy

Mesh：

Substances：

Year:  2021        PMID： 33579808      PMCID： PMC9364763          DOI： 10.2967/jnumed.120.258103

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   11.082


× No keyword cloud information.
  3 in total

1.  Preclinical Pharmacokinetics and Dosimetry Studies of 124I/131I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models.

Authors:  Ian R Marsh; Joseph Grudzinski; Dana C Baiu; Abigail Besemer; Reinier Hernandez; Justin J Jeffery; Jamey P Weichert; Mario Otto; Bryan P Bednarz
Journal:  J Nucl Med       Date:  2019-03-29       Impact factor: 10.057

Review 2.  PSMA ligands in prostate cancer - Probe optimization and theranostic applications.

Authors:  Susanne Lütje; Roger Slavik; Wolfgang Fendler; Ken Herrmann; Matthias Eiber
Journal:  Methods       Date:  2017-06-28       Impact factor: 3.608

3.  Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients.

Authors:  Matthias D'Huyvetter; Jens De Vos; Vicky Caveliers; Ilse Vaneycken; Johannes Heemskerk; Francois P Duhoux; Christel Fontaine; Marian Vanhoeij; Albert D Windhorst; Frank van der Aa; N Harry Hendrikse; Jos L E Eersels; Hendrik Everaert; Pieterjan Gykiere; Nick Devoogdt; Geert Raes; Tony Lahoutte; Marleen Keyaerts
Journal:  J Nucl Med       Date:  2020-12-04       Impact factor: 10.057
  3 in total
  1 in total

1.  The cultivation of supply side data science in medical imaging: an opportunity to define the future of global health.

Authors:  Adam Kesner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.